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The effects of amitraz, a formamidine pesticide, were
investigated in four-week old outbred male Wistar rats on
certain classic toxicological and haematological parame-
ters as well as on specific immune functions. The animals
were treated, per os by gavage for 28 days, in a five-day
treatment two days break system, with 26.5, 21.1, 10.6
and 5.29 mg/kg/day amitraz. On the 29th day, organ
weights of the thymus, heart, lung, spleen, liver, kidneys,
adrenals, testicles and popliteal lymph node; WBC and
RBC counts, Ht, MCV, haemoglobin; and cell content of
the femoral bone marrow were determined. In two sepa-
rate groups, the effects of amitraz on the PFC content of
the spleen, and on the maximum level and time course of
DTH reaction, were investigated.
Amitraz in 26.5 mg/kg dose increased relative adrenal
weight, and decreased relative liver weight, MCV value,
PFC content of the spleen, and the maximum level of
DTH reaction. The 21.1 mg/kg dose decreased only MCV
value, while 10.6 mg/kg elevated the liver-to-brain
weight ratio. Based of these findings, a NOEL dose of
5.29 mg/kg was determined for amitraz in this experi-
mental system; while the LOEL doses were 10.6 mg/kg
for the general toxicological, 21.1 mg/kg for the haema-
tological and 26.5 mg/kg for the immune function
parameters. The results show that the exposure sensitiv-
ity of these immune functions to amitraz is lower than
that of some other toxicological and haematological
parameters. Human & Experimental Toxicology (2007)
26, 441–445
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Introduction
The toxic effects of larger doses of pesticides on the
human population are mainly well documented.
There are, however, no convincing epidemiological
data to prove or exclude the immunotoxic potential
of repeated small doses of pesticides. Beside the
number of disturbing factors (differences in
lifestyle, exposure conditions, immunological histo-
ry of the participants, and so on) which can affect
the immunological parameters measured, there are
significant differences in aim and design (duration,
parameters investigated, and so on) of the epidemi-
ological studies available.1 As a consequence, the
only way at present to obtain information about the
immunotoxic or immunomodulatory potential of
low dose pesticides exposures are animal studies.
The formamidine pesticide amitraz is commonly
used as an animal ectoparasiticide for the control of
ticks, mites and lice on cattle, dogs, goats, pigs and
sheep. In the agriculture, it is applied as an insecti-
cide against mites, pear suckers, scale insects,
mealybugs, whitefly and aphids.2 Widespread
application may result in exposure of the popula-
tion by lower amitraz doses for a long period of
time, mainly via food. In a study with amitraz-
sprayed dates the initial level of 0.34 mg/kg
decreased in 21 days to 0.02 mg/kg which was still
above the MRL (0.01 mg/kg).3 In such cases, the
non-observation of the restricted entry interval can
result in food-borne exposure above MRL. Other
commodities, including tea, were likewise of con-
cern and were tested for amitraz residues.4 Also
food samples, taken randomly in Hungarian food
markets, had occasionally pesticide residues well
above the MRL, according to the reports of
Hungarian authorities (www.ontsz.hu). In certain
occupations – producers, pesticide workers, farm
owners, animal breeders, veterinarians and so on –
the risk of exposure to higher doses is also present.
Influence on the immune system has been observed
in case of a number of environmental contaminants.
The possible consequences include increased risk of
malignant tumours, decreased defence against infec-
tious agents, and increased occurrence of allergic and
autoimmune diseases. In case of amitraz, the general
toxic effects, as well as behavioural, neuro-, and
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reproductive toxicity, have already been investigated
in rats and mice4–12 but, except for potentially causing
delayed contact hypersensitivity,13 literature data on
its effects on the immune system are missing. The aim
of the present study was thus to investigate the effects
of amitraz on certain specific immune functions (PFC
assay, DTH reaction), and to compare the sensitivity of
these parameters in the detection of amitraz exposure
with that of certain general toxicological and haema-
tological parameters.
Materials and methods
Amitraz of 98.2% purity was the precious donation of
Hockley Int. Ltd, UK. Sheep red blood cells (SRBC)
were produced by Philmaster Ltd. Budapest, Hungary;
RPMI-1640 and Freund’s Complete Adjuvant (FCA),
by SIGMA, USA; Keyhole Limpet Haemocyanin
(KLH), by Calbiochem, USA. The other materials were
supplied by REANAL Factory of Laboratory Chemi-
cals, Budapest, Hungary.
Four weeks old outbred male Wistar rats, obtained
from the SPF breed of Charles River Ltd., Hungary,
were used in the experiments. The animals were
kept under conventional conditions (up to five rats
per cage, 12 hour light–dark cycle, 22  2°C,
70  10% humidity), standard rodent food and
water was available at all times. Amitraz was sus-
pended in 1% methylcellulose containing 0.1%
Tween 80 and applied per os by glass gavage in a vol-
ume of 5 mL/kg. Controls received only vehicle.
Experimental design
Acute oral LD50 of amitraz was determined by the
Litchfield-Wilcoxon method14 in nine-week old
male Wistar rats using six doses (1000, 710, 510,
360, 260 and 190 mg/kg) and six animals per dose.
After 14 days observation, the surviving animals (in
the 510–190 mg/kg dose range) were dissected to
determine certain general toxicological and haema-
tological parameters (see below). In the dose-effect
experiment 1/20, 1/25, 1/50 and 1/100 LD50 of ami-
traz (26.5; 21.1; 10.6; and 5.29 mg/kg, respectively)
was given to 24 rats/dose in a five-day treatment two
days break system for 28 days. Eight rats per dose
were used for toxicological and haematological
examinations, another eight per dose for PFC assay,
and eight per dose for DTH reaction.
Parameters examined
Toxicological and haematological parameters
The body weight of the animals was measured once
a week (always on the same day). The organ weights
of brain, thymus, lung, heart, liver, spleen, kidneys,
adrenals, testicles and popliteal lymph nodes were
determined on the 29th day. For haematological
studies, blood was taken from the abdominal aorta.
The absolute white blood cell (WBC) and red blood
cell (RBC) count, haematocrit (Ht), mean cell volume
of RBC-s (MCV), and the cell content of the femoral
bone marrow were measured by a PS-5 Blood Cell
Counter (Medicor, Hungary) as described.15 The
haemoglobin content was determined by a Minilab-
540 photometer (Medicor, Hungary).
IgM-PFC assay The animals were immunized by
2  109 SRBC i.p. in 0.4 mL PBS on the 25th day of
treatment. On the 29th day, the spleen was removed
and the IgM-PFC number calculated for 106 spleen
cells and for the whole spleen was determined.15
Delayed type hypersensitivity (DTH) The animals
were immunized s.c. at the base of tail by 1 mg KLH
in 0.4 mL antigen preparation (KLH was dissolved
in sterile PBS and emulgated by equal volume of
FCA) on the 14th day of treatment. The reaction was
challenged on the 29th day by injecting 17.5 g KLH
in 50 L PBS into the left hind footpad. Footpad
thickness was measured just before, 24, and 48
hours after challenge by a Microstat micrometer
(CADAR, U.K.), and specific footpad swelling (D%)
was calculated as described.15
The distribution of data was checked for normali-
ty by the Kolmogorov–Smirnov test. Depending on
the distribution, the statistical analyses were carried
out by ANOVA or by Kruskal–Wallis non-parametric
ANOVA setting the probability level to P  0.05. In
case of ANOVA, post hoc analysis of group
differences was performed by LSD test, while group
comparisons following the Kruskal–Wallis ANOVA
were performed by Mann–Withney test. Statistical
analysis was performed by the Statistica for
Windows 4.0 software.
Results
The acute oral LD50 of amitraz proved to be 
529 [417–670] mg/kg. Single oral doses of 190–
1000 mg/kg, applied in the LD50 determination,
resulted in excitability, aggression in response to
handling, coolness to touch, hunched posture, and
piloerection within 1–2 hours after administration;
the symptoms subsiding with decreasing dose.
Toxicological and haematological data of the surviv-
ing animals in the 190–510 mg/kg dose range are
presented in Tables 1 (A, B) and 2. All four doses
(510, 360, 260 and 190 mg/kg) significantly
decreased the body weight gain of the animals by
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the 7th day after treatment, while on the 14th day,
only the body weight of the 360 and 260 mg/kg 
dose groups were retarded compared to controls
(Table 1A). As presented in Table 1B, the higher
doses elevated the relative liver, spleen, and kidney
weights in a dose dependent manner; and the
510 mg/kg dose also decreased the relative weight of
testicles. The three higher doses significantly dimin-
ished the cell content of the femoral bone marrow
and, except the 360 mg/kg dose, the mean volume of
RBCs (Table 2).
During the cage-side observations in the subacute
studies, no abnormalities (such as those seen in 
the LD50 determination) were observed. Neither of
the doses applied affected the body weight gain or
the absolute brain weight. The weight of adrenals 
related to 100 g body weight increased only at the
highest (26.5 mg/kg) dose (P  0.05). The liver to
brain weight ratio was elevated at the 10.6 mg/kg
(P  0.05), and diminished at the 26.5 mg/kg dose
(P  0.001; Figure 1). Among the haematological
parameters measured, only MCV decreased at the
two higher doses (P  0.05 in both cases; Table 3).
The 26.5 mg/kg dose significantly reduced the spleen
cell number of the animals immunised with SRBC
(P  0.005) but had no effect on the number of
plaques formed from 106 spleen cells. As a conse-
quence, the PFC content of the spleen also decreased
(P  0.002; Figure 2). The two higher doses
decreased the maximum and shortened the decay of
DTH reaction but the difference was statistically sig-
nificant only at the highest dose (P  0.05; Figure 3).
Discussion
The results of the present study are comparable with
several findings reported in the literature. The acute
oral LD50 of amitraz was 529 mg/kg in this study. In
the literature, data between 523 and 800 mg/kg are
Table 1 Effect of a single amitraz dose on body weight gain (A), and on relative organ weights (B) related to 100 g body weight or to
brain in the surviving animals (X  SE)
Body weight (g)  SE
Dose (mg/kg) Day 0 Day 7 Day 14
510 (3) 176  0.88 160  3.33* 280  5.77
360 (5) 162  0.86 160  3.74* 240  8.37*
260 (6) 180  0.76 188  4.47* 245  4.01*
190 (6) 173  0.76 202  3.33* 292  3.07
Control (6) 170  0.65 230  4.08 282  7.07
Organ weight to brain (g/g or mg/g)  SE Organ weight to 100 g body weight (g/100 g)
Dose (mg/kg) weight Liver Spleen Kidneys Testicles Liver Spleen Kidneys Testicles
510 (3) 1.75 7.46 0.597 1.34 1.45 4.66 0.372 0.836 0.911
0.04 0.28* 0.08* 0.06 0.09 0.07* 0.04 0.02 0.08*
360 (5) 1.77 6.35 0.543 1.21 1.64 4.69 0.403 0.894 1.22
0.04 0.27 0.03 0.03 0.03 0.10* 0.03* 0.03* 0.06
260 (6) 1.91 5.83 0.408 1.25 1.71 4.55 0.319 0.976 1.34
0.04 0.32 0.02 0.06 0.07 0.17* 0.01 0.02* 0.07
190 (6) 1.85 6.15 0.478 1.19 1.72 3.89 0.303 0.752 1.09
0.05 0.15 0.01 0.01 0.06 0.11 0.01 0.01 0.04
Control (6) 1.86 5.50 0.467 1.14 1.74 3.71 0.316 0.770 1.18
0.01 0.35 0.02 0.03 0.02 0.24 0.01 0.01 0.02
n  Number of survivors; *P  0.05 related to control; the day 0 values involve only the starting body weight of the surviving animals.
Table 2 Changes in the haematological parameters following single large doses of amitraz (X  SE)
Dose (mg/kg) WBC (106/mL) RBC (109/mL) MCV (fl) Ht (%) Cell/femur (108) Hb (g/L)
510 (3) 4.40  0.88 6.09  0.87 63.3  0.63* 38.5  3.77 1.68  0.06* 14.1  2.60
360 (5) 8.52  0.86 6.21  0.44 66.0  0.71 40.9  2.98 1.40  0.18* 12.5  0.39
260 (6) 7.52  0.76 6.51  0.61 63.4  1.25* 46.5  2.54 1.61  0.17* 13.3  0.40
190 (6) 7.52  0.99 6.90  0.24 65.2  0.50 45.0  1.35 1.89  0.15 12.7  0.31
Control (6) 6.10  0.89 6.87  0.14 67.2  0.82 46.2  1.07 2.17  0.07 12.5  0.35
( ) Number of survivors; *P  0.05 related to control.
Abs. brain
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found, depending on the rat strain used and the
purity of amitraz.5,6,13
A 90 days treatment of male Ash-Wistar rats with
12 mg/kg amitraz resulted in 8% retardation of body
weight gain and in reduction of relative liver weight
by 6%.13 Ueng et al.16 found that 25 and 50 mg/kg
amitraz, administered on three consecutive days
i.p., elevated the relative liver weight of female
Wistar rats by 12 and 18%, respectively. The higher
dose also decreased the body weigh by 14%, and
increased the relative lung (30%), kidney (13%) and
adrenal (26%) weight. In the present study,
10.6 mg/kg amitraz elevated the relative liver
weight by 22% while 26.5 mg/kg resulted in a 20%
reduction. The latter dose also increased the relative
adrenal weight by 37%. According to these results,
the direction of change of the relative liver weight
seems to be dose-dependent.
The haematological effects were investigated fol-
lowing a three-week inhalation (six hours a day)
exposure to 0.01, 0.1 and 1.0 mg/L amitraz concentra-
tions.13 Beside the characteristic toxic signs and body
weight loss at the highest concentration, reduced
packed cell volume, haemoglobin, and red cell
Figure 1 Effect of four-week amitraz treatment on the relative liver and adrenal weights (X  SE, n  8,* P  0.05).
Table 3 Effect of four-week amitraz treatment on certain haematological parameters (X  SE)
Dose (mg/kg) WBC (106/mL) RBC (109/mL) MCV (fl) Ht (%) Cell/femur (108) Hb (g/L)
26.5 8.63  1.86 7.57  0.38 65.8  0.97* 43.8  1.65 2.25  0.29 13.0  0.25
21.1 11.1  2.01 6.31  0.52 64.3  1.35* 42.7  2.79 1.71  0.28 13.4  0.93
10.6 8.65  1.57 6.57  0.08 68.9  0.47 45.3  0.75 1.99  0.13 13.8  0.90
5.29 7.33  0.94 6.53  0.15 69.1  0.83 44.8  1.21 2.17  0.08 12.7  0.19
Control 7.31  0.51 6.80  0.09 68.2  0.56 46.3  0.72 2.19  0.11 12.8  0.28
*P  0.05.
Figure 2 Changes of the PFC content of the spleen following a
four-week oral treatment with amitraz (X  SE, n  8, *P  0.05).
Figure 3 Effect of four-week amitraz treatment on the DTH reac-
tion measured by footpad swelling assay (X  SE, n  8).
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number was observed. In our system, which repre-
sents a lower exposure level, neither toxic signs nor
body weight loss were observed, and only the mean
volume of the red blood cells (MCV) decreased at the
two higher doses. The reduction of haematocrit was
less pronounced and not statistically significant.
The effect of amitraz on the humoral immune
response was detected by PFC assay. The reduced
PFC content of the spleen was the consequence of
the decreased cell count of the spleen in the ani-
mals immunised with SRBC, as the number of
plaques formed from 106 spleen cells did not
change. This finding can be explained by cell loss
or cell damage in the spleen rather than by a direct
effect on the specific immune response. The maxi-
mum and time course of DTH reaction, which was
applied for characterisation the effect of amitraz on
one of the main routes of cellular immune
response, also decreased at the two higher doses
but it was statistically significant only at the
26.5 mg/kg dose.
The NOEL dose (the dose not affecting any param-
eter investigated) proved to be 5.29 mg/kg in the
present system. In different experimental systems in
rats, NOAEL (non observed adverse effect level)
values of oral amitraz exposure varied between 1.3
and 12 mg/kg/day, depending on the aim of studies
and duration of treatment.13 In our experiments,
10.6 mg/kg amitraz elevated the relative liver weight
versus control but this effect was not dose-dependent.
In addition, the relative liver weight in this group was
not significantly different from that in the lower
(2.29 mg/kg) and the higher (21.1 mg/kg) dose groups.
The 21.1 mg/kg dose altered only the MCV value but
had no effect on the other parameters investigated.
The 26.5 mg/kg dose decreased relative liver weight,
MCV value, the cellularity of the spleen of the animals
immunized by SRBC, and the maximum of DTH reac-
tion; and increased the relative adrenal weight. So, in
respect of the effect on the specific immune functions,
26.5 mg/kg can be regarded as LOEL in the present
experimental system. The exposure sensitivity of the
immune function assays in detection of effects after
four weeks oral amitraz treatment proved to be lower
than that of certain toxicological and haematological
parameters investigated.
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